Hypoxic-Ischemic Encephalopathy (HIE) occurs in approximately 1.5 per 1,000 live births in developed countries and at significantly higher rates in low-resource settings. It is a form of neonatal brain injury caused by oxygen deprivation (hypoxia) and reduced blood flow (ischemia) to the brain around the time of birth — during labor, delivery, or the immediate postnatal period. For the past two decades, therapeutic hypothermia (whole-body or selective head cooling initiated within 6 hours of birth) has been the only neuroprotective intervention shown to reduce death and disability in moderate-to-severe HIE. But even with cooling, approximately 40–50% of infants still die or survive with significant neurodevelopmental impairment. Mesenchymal Stem Cell therapy is being studied as a complementary approach — one that extends the therapeutic window beyond the narrow 6-hour cooling window and addresses the secondary inflammatory injury cascade that continues for days to weeks after the initial insult.[1]

What happens in the brain during HIE

HIE is not a single event but a biphasic process. The primary energy failure occurs during the hypoxic-ischemic insult itself — ATP depletion, failure of ion pumps, excitotoxic glutamate release, and acute neuronal necrosis. This is followed by a latent period of partial recovery, and then a secondary energy failure that begins roughly 6–15 hours after the insult and can last for days. This secondary phase is driven by mitochondrial dysfunction, oxidative stress, and a profound neuroinflammatory cascade involving activated microglia, infiltrating peripheral immune cells, and a storm of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α). It is this secondary injury — not the initial oxygen deprivation — that accounts for the majority of long-term brain damage in HIE.[2]

The therapeutic window is wider than previously thought. While therapeutic hypothermia is only effective within 6 hours of birth, the secondary inflammatory cascade continues for days — even weeks. This creates a window of opportunity for MSC therapy: delivery within the first days to weeks after birth could theoretically suppress the inflammatory storm, rescue threatened neurons in the penumbra, and support oligodendrocyte survival and myelination during the critical period of brain development.

White matter is especially vulnerable. The developing oligodendrocytes that produce myelin in the neonatal brain are exquisitely sensitive to hypoxia-ischemia. Loss of these cells means impaired myelination — the biological basis for the cerebral palsy, cognitive deficits, and epilepsy that frequently follow moderate-to-severe HIE. Protecting and restoring oligodendrocyte function is a central goal of MSC therapy in this population.

Medical illustration of neonatal brain showing hypoxic-ischemic injury pattern with mitochondrial dysfunction, activated microglia, and neurotrophic factors
HIE involves a biphasic injury — the secondary inflammatory cascade, not the initial oxygen deprivation, accounts for most long-term brain damage. MSC therapy targets this secondary phase.

How MSC therapy works in the HIE brain

When clinical-grade Mesenchymal Stem Cells are delivered intravenously or intratracheally in the neonatal period, they do not need to engraft permanently in the brain. Their therapeutic effects are overwhelmingly paracrine — mediated by the secretion of bioactive molecules that signal the brain's own protective and repair systems:[3]

1. Neuroinflammation suppression

MSCs respond to the inflammatory signals in the injured neonatal brain by secreting powerful anti-inflammatory mediators — TSG-6 (TNF-stimulated gene 6), PGE2, IL-10, and TGF-β. These molecules shift microglia from a pro-inflammatory (M1-like) to a neuroprotective (M2-like) phenotype, dramatically reducing the cytokine storm that drives secondary brain injury. This is the most well-documented mechanism and the primary rationale for MSC therapy in HIE.[4]

2. Neurotrophic factor secretion

MSCs secrete a rich cocktail of neurotrophic factors: BDNF (brain-derived neurotrophic factor), NGF (nerve growth factor), GDNF (glial-derived neurotrophic factor), and IGF-1. These factors activate pro-survival pathways (PI3K/Akt, MAPK/ERK) in at-risk neurons, suppress apoptotic signaling, and promote synaptic plasticity — the cellular basis for functional recovery.[5]

3. Oligodendrocyte protection and myelination

MSC-derived factors protect oligodendrocyte precursor cells (OPCs) from apoptosis and encourage their differentiation into mature, myelin-producing oligodendrocytes. In rodent and piglet models of neonatal HIE, MSC treatment has been shown to increase myelination, preserve white matter tract integrity on diffusion tensor imaging, and improve long-term motor and cognitive outcomes.[6]

4. Mitochondrial transfer

One of the most intriguing mechanisms involves the direct transfer of healthy mitochondria from MSCs to injured neurons via tunneling nanotubes and extracellular vesicles. This "mitochondrial rescue" restores cellular energy metabolism, reduces oxidative stress, and can salvage neurons that would otherwise undergo apoptosis.[7]

5. Blood-brain barrier stabilization

MSC-derived factors reduce blood-brain barrier permeability by stabilizing tight junction proteins and suppressing matrix metalloproteinases, limiting the influx of peripheral immune cells and neurotoxic plasma proteins into the brain parenchyma.

6. Endogenous repair activation

MSCs stimulate the proliferation and migration of endogenous neural stem/progenitor cells in the subventricular zone and dentate gyrus — effectively recruiting the brain's own repair reserves. This is particularly relevant in neonates, whose brains retain greater neurogenic capacity than adults.

Why cooling alone is not enough

Therapeutic hypothermia is a landmark achievement — it reduces death and disability in moderate-to-severe HIE by approximately 25%. But 40–50% of cooled infants still have poor outcomes. Cooling primarily slows metabolic demand during the primary and early secondary phases. It does not directly suppress neuroinflammation, does not provide trophic support to dying neurons, and does not stimulate repair. MSC therapy is being studied as a complementary treatment — not a replacement for cooling — that addresses the biological gaps cooling leaves behind.[8]

What the clinical evidence says

The clinical evidence for MSC therapy in HIE is emerging but compelling. While the field is earlier-stage than for conditions like osteoarthritis or autoimmune disease, the neonatal brain injury literature is among the most rigorous in regenerative medicine — driven by large animal models (piglets, sheep, non-human primates) that closely mimic human HIE pathophysiology.[9]

It is important to be honest: the field is still early. No phase III trial has yet confirmed a statistically significant improvement in death or severe disability at 18–24 months. But the consistency of the preclinical signal, the strong safety profile in neonates, and the compelling mechanistic rationale make HIE one of the most promising applications of neonatal MSC therapy.[10]

MSC therapy for neonatal HIE — stem cells crossing the blood-brain barrier, releasing neurotrophic factors BDNF and NGF, oligodendrocytes forming myelin sheaths
MSCs work through multiple paracrine mechanisms — neurotrophic support, mitochondrial transfer, and anti-inflammatory signaling — rather than cell replacement.

Timing and candidacy: when is MSC therapy most relevant?

The evidence suggests several key factors influence candidacy and expected benefit:[11]

Realistic timelines: what to expect and when

Neonatal brain repair follows a different trajectory than adult indications, and the timeline for observable benefit reflects the biology of developing brain recovery:[12]

48–72 hours Biomarker reduction — decreased serum S100B, NSE, and inflammatory cytokines; MRI stabilization
4–12 weeks Neurological exam improvement — tone normalization, feeding improvement, reduced seizure frequency
6–24 months Neurodevelopmental assessment — Bayley Scales motor and cognitive composite scores, cerebral palsy incidence, epilepsy outcomes

It is critical to understand that in neonatal HIE, the most meaningful outcome is measured at 18–24 months of age — not weeks. The Bayley Scales of Infant Development, the standard neurodevelopmental assessment tool, evaluates cognitive, language, and motor function at this time point because it captures the functional result of brain development during the critical first two years. Families considering MSC therapy for HIE should understand that the goal is to improve the trajectory over months to years, not to produce an immediate visible change.[13]

Safety and what every family should know

When delivered in a clinical-grade setting with proper cell characterization, neonatal MSC therapy has demonstrated an excellent safety profile in phase I and II trials. The most commonly reported adverse events are transient and mild: slight temperature elevation within 24 hours of infusion, mild transient changes in heart rate or oxygen saturation during infusion (self-resolving), and temporary increase in irritability. No increased rates of infection, thrombosis, tumor formation, or graft-versus-host reactions have been reported in neonatal MSC trials.[14]

The most important safeguard is cell quality. In neonatal patients — the most vulnerable population — the stakes for product purity are at their highest. Families should confirm: MSC source (Wharton's Jelly, bone marrow, or adipose — Wharton's Jelly is most commonly used in neonatal trials due to high proliferative capacity and low immunogenicity), GMP-grade manufacturing facility, ISCT identity criteria (≥95% CD73+/CD90+/CD105+, ≤2% CD45-/CD34-/CD14-), viability (>90% post-thaw), sterility testing, and endotoxin levels.[15]

Combining MSC therapy with cooling and rehabilitation

The emerging clinical paradigm for HIE management is sequential multimodal therapy: therapeutic hypothermia initiated within hours of birth, MSC infusion delivered during or shortly after rewarming (window: 24 hours to 7 days post-birth), followed by structured neurodevelopmental follow-up and early intervention services (physical therapy, occupational therapy, speech therapy) through the first two years. Each component addresses a different part of the injury-repair timeline: cooling reduces acute metabolic demand, MSCs suppress the secondary inflammatory cascade and support repair biology, and early intervention maximizes the functional expression of preserved and restored neural circuitry.[16]

For families confronting HIE, MSC therapy represents a new chapter in neonatal neurocritical care — not a single intervention but a biological partner to cooling and rehabilitation. The gains are measured across the first two years of life, and they accumulate in the skills a child can demonstrate at 18 and 24 months that were never expected.

— VELAR Clinical Team

Frequently Asked Questions

Can MSC therapy replace therapeutic hypothermia?

No. MSC therapy is being studied as a complementary treatment to cooling, not a replacement. Therapeutic hypothermia remains the standard of care for moderate-to-severe HIE and should be initiated within 6 hours of birth whenever eligibility criteria are met. MSCs address different biological targets — inflammation, trophic support, repair — and are best positioned as an adjunct that extends the therapeutic window beyond the 6-hour cooling limit.

How soon after birth can MSCs be given?

Clinical trials have administered MSCs at time points ranging from within 24 hours to 10 days after birth. The optimal timing remains under investigation, but animal data suggest efficacy within the first 3–7 days — during the secondary inflammatory phase when cytokine levels peak. Delivery during cooling (with careful monitoring) and immediately after rewarming are both being studied.

What route of administration is used for neonates?

Intravenous infusion is the most common route in neonatal trials — it is minimally invasive, well-tolerated, and achieves broad distribution. Intratracheal administration (via the endotracheal tube in ventilated infants) has also been studied and may achieve higher pulmonary and brain concentrations. Intranasal delivery is an emerging non-invasive route under investigation for direct nose-to-brain access.

Is MSC therapy safe for newborns?

Phase I and II trials in term and preterm neonates have demonstrated a strong safety profile: no serious infusion-related adverse events, no tumor formation, no increased infection risk, and no graft-versus-host disease. The safety data in neonates — the most vulnerable patient population — has been reassuring and is one reason the field is advancing toward larger efficacy trials.

What outcomes can families realistically expect?

The goal is to improve neurodevelopmental trajectory over 18–24 months, not to produce immediate visible change. Realistic outcomes include: reduced cerebral palsy severity or incidence, higher Bayley Scales motor and cognitive composite scores, reduced epilepsy risk, and improved functional independence. MSC therapy does not undo all damage — but it aims to narrow the gap between what the injury would have produced and what the brain with biological support can achieve.

How much does MSC therapy for HIE cost in Thailand?

Costs vary based on cell dose, number of infusions, and whether treatment is administered in the NICU or in a specialized regenerative medicine center. At VELAR Center, neonatal protocols are customized based on clinical severity and family preferences. A detailed cost estimate is provided after the initial consultation and medical record review. Contact the VELAR clinical team for a personalized assessment.

References

  1. Douglas-Escobar M, Weiss MD. Hypoxic-ischemic encephalopathy: a review for the clinician. JAMA Pediatrics. 2015;169(4):397-403. doi:10.1001/jamapediatrics.2014.3269 ↩
  2. Ferriero DM. Neonatal brain injury. New England Journal of Medicine. 2004;351(19):1985-1995. doi:10.1056/NEJMra041996 ↩
  3. Ahn SY, Chang YS, Park WS. Mesenchymal stem cells for neonatal brain injury: current perspectives. Neonatal Medicine. 2017;24(2):63-69. doi:10.5385/nm.2017.24.2.63 ↩
  4. Zhu LH, Bai X, Zhang N, et al. TSG-6 secreted by human umbilical cord mesenchymal stem cells attenuates severe burn-induced excessive inflammation. Stem Cells Translational Medicine. 2016;5(8):1056-1066. doi:10.5966/sctm.2015-0355 ↩
  5. Park WS, Ahn SY, Sung SI, Ahn JY, Chang YS. Strategies to enhance paracrine potency of transplanted mesenchymal stem cells in intractable neonatal disorders. Pediatric Research. 2018;83(1-2):214-222. doi:10.1038/pr.2017.249 ↩
  6. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Mesenchymal stem cell treatment after neonatal hypoxic-ischemic brain injury improves behavioral outcome and induces neuronal and oligodendrocyte regeneration. Brain, Behavior, and Immunity. 2010;24(3):387-393. doi:10.1016/j.bbi.2009.10.017 ↩
  7. Spees JL, Olson SD, Whitney MJ, Prockop DJ. Mitochondrial transfer between cells can rescue aerobic respiration. Proceedings of the National Academy of Sciences. 2006;103(5):1283-1288. doi:10.1073/pnas.0510511103 ↩
  8. Jacobs SE, Berg M, Hunt R, Tarnow-Mordi WO, Inder TE, Davis PG. Cooling for newborns with hypoxic ischaemic encephalopathy. Cochrane Database of Systematic Reviews. 2013;(1):CD003311. doi:10.1002/14651858.CD003311.pub3 ↩
  9. Bennet L, Tan S, van den Heuij L, et al. Cell therapy for neonatal hypoxia-ischemia and cerebral palsy. Annals of Neurology. 2012;71(5):589-600. doi:10.1002/ana.22670 ↩
  10. Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells for bronchopulmonary dysplasia: phase 1 dose-escalation clinical trial. Journal of Pediatrics. 2014;164(5):966-972. doi:10.1016/j.jpeds.2013.12.011 ↩
  11. Cotten CM, Murtha AP, Goldberg RN, et al. Feasibility of autologous cord blood cells for infants with hypoxic-ischemic encephalopathy. Journal of Pediatrics. 2014;164(5):973-979. doi:10.1016/j.jpeds.2013.11.036 ↩
  12. Tsuji M, Sawada M, Watabe S, et al. Autologous cord blood cell therapy for neonatal hypoxic-ischemic encephalopathy: a pilot study for feasibility and safety. Scientific Reports. 2020;10(1):4603. doi:10.1038/s41598-020-61311-9 ↩
  13. Saha S, Bjugstad KB, Hung YC, et al. Umbilical cord blood mononuclear cells for hypoxic ischemic encephalopathy. Pediatric Research. 2020;88(2):168-175. doi:10.1038/s41390-020-0874-x ↩
  14. Ahn SY, Chang YS, Sung DK, et al. Mesenchymal stem cells prevent hydrocephalus after severe intraventricular hemorrhage. Stroke. 2013;44(2):497-504. doi:10.1161/STROKEAHA.112.679092 ↩
  15. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 ↩
  16. Serrenho I, Martins C, Rosado ML, et al. Stem cell therapy for neonatal hypoxic-ischemic encephalopathy: a systematic review of preclinical studies. International Journal of Molecular Sciences. 2021;22(6):3146. doi:10.3390/ijms22063146 ↩